Ozempic/Wegovy/Rybelsus claims

Ozempic/Wegovy/Rybelsus claims video

New medical research suggests that GLP-1 agonists, sold under the famous brand names Ozempic, Wegovy, and Rybelsus, can potentially increase the risk of gastroparesis (stomach paralysis) and bowel obstruction in people who use these drugs strictly for weight loss. Doctors prescribe these three medications to treat type 2 diabetes; however, they are also heavily marketed as weight-loss drugs. GLP-1 agonists, such as Ozempic and Wegovy, are injectable medications, while Rybelsus comes in pill form. If you have taken GLP-1 agonists and you developed gastroparesis or bowel obstruction, we encourage you to contact our law firm, as we may be able to recover financial compensation for you.

Claim Application

How Ozempic/Wegovy/Rybelsus can cause injuries

Semaglutide (the active ingredient in Ozempic/Wegovy/Rybelsus) imitates a hormone called glucagon-like peptide-1 that is naturally produced when food is consumed. Semaglutide helps regulate appetite and reduce cravings. It prompts the stomach to empty more slowly. As a result, many people who struggle with obesity have lost weight while using these drugs, which have semaglutide as the active ingredient: 

  • Ozempic is a once-weekly semaglutide injection approved by the Food and Drug Administration in 2017 to treat type 2 diabetes in adults. While it is not approved for weight loss, some doctors prescribe it for this purpose. The drug keeps gaining attention, especially on social media, as celebrities and TikTok influencers have been using it to lose weight in short time frames.
  • Wegovy is a once-weekly semaglutide injection. The Food and Drug Administration approved this medication in 2021 for weight loss in adults and teens. It has a higher dose of semaglutide than Ozempic.
  • Rybelsus, a once-daily oral pill - is prescribed for adults to manage their type 2 diabetes, and it is not approved for weight loss.

According to the American College of Gastroenterology, a medication that delays stomach emptying may also cause stomach paralysis. The most severe side effect of these drugs is gastroparesis, the paralysis of the stomach. Stomach paralysis is a severe disorder in which the movement of food is significantly slowed down or stopped from the stomach to the small intestine. A significant fact is that there is no known cure for gastroparesis. Another injury semaglutide may cause is bowel obstruction.

Eligibility for Ozempic/Wegovy/Rybelsus claims

If you were not diagnosed with stomach paralysis or bowel obstruction before using Ozempic, Wegovy, or Rybelsus, your condition was most likely caused by these drugs. However, only a gastroenterologist can determine whether the drugs are the culprit behind your condition. Both stomach paralysis and bowel obstruction are severe health conditions; therefore, if you experience any symptoms, you should seek immediate medical attention and get an accurate diagnosis. When you have a diagnosis, do not hesitate to contact our law firm, as you might be eligible to file an Ozempic/ Wegovy/ Rybelsus claim and obtain rightful financial compensation, which can cover your medical expenses.

Our team of experts is ready to thoroughly and carefully review your case to determine whether you are eligible to file a claim. If you are ready to file a claim against the liable manufacturers, you need to meet the following criteria:

  • no gastroparesis or bowel obstruction diagnoses beforeusing Ozempic, Wegovy, or Rybelsus
  • must have been diagnosed with gastroparesis or bowel obstruction after using Ozempic, Wegovy, or Rybelsus
  • must have been hospitalized or visited the ER
  • must be 75 of age or younger

Patients on GLP-1 agonist drugs have a higher risk of gastrointestinal disorders

Semaglutide Side Effects

A recent study published by researchers from the University of British Columbia shows that compared to bupropion-naltrexone, patients on GLP-1 agonist drugs have:

This is the first epidemiological study that links the weight loss drugs Ozempic, Wegovy, and Rybelsus to severe gastrointestinal conditions.

According to medical researchers and gastroenterologists, the most common side effect of Ozempic is nausea, which occurs in approximately 15% to 20% of patients. These side effects occurred at rates higher than those in the placebo-treated groups, and more patients using Ozempic (0.5 mg—3.1% and 1 mg—3.8%) stopped the treatment due to gastrointestinal side effects than patients receiving the inactive treatment (0.4%).

Ozempic/Wegovy/Rybelsus claims, settlements, and litigation

Ozempic, Wegovy, and Rybelsus are manufactured by Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in 9 countries and affiliates or offices in 5 countries. The first lawsuit was filed against Novo Nordisk by Jaclyn Bjorklund, a 44-year-old woman from Louisiana who was diagnosed with gastroparesis after using Ozempic on August 2, 2023. The woman used the drug for over a year; she sued the manufacturer for failing to warn of the risk of gastrointestinal conditions that could be caused by using the medication. Law firms are investigating over 500 other inquiries from clients struggling with Ozempic side effects across 45 states.

We offer legal assistance in filing Ozempic/Wegovy/Rybelsus claims

Have you taken Ozempic, Wegovy, or Rybelsus and been diagnosed with stomach paralysis or bowel obstruction? If yes, we strongly encourage you to contact us. With over 35 years of experience assessing personal injury claims, our team of experts will carefully evaluate your case to determine whether you can file a claim and obtain the financial compensation you deserve.

The only documents we will need to assess your case are evidence of you having taken Ozempic, Wegovy, or Rybelsus and your medical records with your diagnosis. We understand how physically and emotionally draining suffering from these conditions can be. Therefore, we will do everything possible to make the legal process as simple as possible for you.